Researcher profile

Tze Leung Lai

Tze Leung Lai contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 17 - UnverifiedVerification L1Unclaimed author
4works
0followers
3topics
1close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

4 published item(s)

preprint2011arXiv

Efficient adaptive designs with mid-course sample size adjustment in clinical trials

Adaptive designs have been proposed for clinical trials in which the nuisance parameters or alternative of interest are unknown or likely to be misspecified before the trial. Whereas most previous works on adaptive designs and mid-course sample size re-estimation have focused on two-stage or group sequential designs in the normal case, we consider here a new approach that involves at most three stages and is developed in the general framework of multiparameter exponential families. Not only does this approach maintain the prescribed type I error probability, but it also provides a simple but asymptotically efficient sequential test whose finite-sample performance, measured in terms of the expected sample size and power functions, is shown to be comparable to the optimal sequential design, determined by dynamic programming, in the simplified normal mean case with known variance and prespecified alternative, and superior to the existing two-stage designs and also to adaptive group sequential designs when the alternative or nuisance parameters are unknown or misspecified.

preprint2011arXiv

Generalized Likelihood Ratio Statistics and Uncertainty Adjustments in Efficient Adaptive Design of Clinical Trials

A new approach to adaptive design of clinical trials is proposed in a general multiparameter exponential family setting, based on generalized likelihood ratio statistics and optimal sequential testing theory. These designs are easy to implement, maintain the prescribed Type I error probability, and are asymptotically efficient. Practical issues involved in clinical trials allowing mid-course adaptation and the large literature on this subject are discussed, and comparisons between the proposed and existing designs are presented in extensive simulation studies of their finite-sample performance, measured in terms of the expected sample size and power functions.

preprint2011arXiv

Multistage tests of multiple hypotheses

Conventional multiple hypothesis tests use step-up, step-down, or closed testing methods to control the overall error rates. We will discuss marrying these methods with adaptive multistage sampling rules and stopping rules to perform efficient multiple hypothesis testing in sequential experimental designs. The result is a multistage step-down procedure that adaptively tests multiple hypotheses while preserving the family-wise error rate, and extends Holm's (1979) step-down procedure to the sequential setting, yielding substantial savings in sample size with small loss in power.

preprint2010arXiv

Approximate Dynamic Programming and Its Applications to the Design of Phase I Cancer Trials

Optimal design of a Phase I cancer trial can be formulated as a stochastic optimization problem. By making use of recent advances in approximate dynamic programming to tackle the problem, we develop an approximation of the Bayesian optimal design. The resulting design is a convex combination of a "treatment" design, such as Babb et al.'s (1998) escalation with overdose control, and a "learning" design, such as Haines et al.'s (2003) $c$-optimal design, thus directly addressing the treatment versus experimentation dilemma inherent in Phase I trials and providing a simple and intuitive design for clinical use. Computational details are given and the proposed design is compared to existing designs in a simulation study. The design can also be readily modified to include a first stage that cautiously escalates doses similarly to traditional nonparametric step-up/down schemes, while validating the Bayesian parametric model for the efficient model-based design in the second stage.